Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 11/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 11/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4350902 | 0.92 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDALOX15TSHR | |
| SCHEMBL4037595 | 0.90 | ICMT (0.39) | KDM4EHPGDGABRA2GABRB2ELANE | |
| SCHEMBL3594920 | 0.87 | PTGER1 (0.41) | PTGER1 | |
| SCHEMBL3595139 | 0.87 | PTGER1 (0.41) | PTGER1KMT2A | |
| SCHEMBL4357086 | 0.87 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDALOX15TSHR | |
| SCHEMBL3592829 | 0.86 | ICMT (0.41) | ALDH1A1KDM4EPTGER1 | |
| SCHEMBL4357082 | 0.86 | ALDH1A1 (0.41) | ALDH1A1KDM4EHPGDALOX15TSHR | |
| SCHEMBL3588519 | 0.85 | CNR1 (0.44) | ALDH1A1KDM4EHPGDALOX15TSHR | |
| SCHEMBL4357149 | 0.83 | CNR1 (0.47) | ALDH1A1KDM4EHPGDALOX15TSHR | |
| SCHEMBL4037638 | 0.83 | RAB9A (0.44) | ALDH1A1KDM4EHPGDALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004240-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20100004240-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | GLAXO GROUP LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | GLAXO GROUP LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| EP-2041127-A2 | INDOLE COMPOUNDS | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| EP-2041126-A1 | INDOLE COMPOUNDS HAVING AFFINITY TO THE EP1 RECEPTOR | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008006795-A2 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006794-A1 | INDOLE COMPOUNDS HAVING AFFINITY TO THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | PTGER1, PTGER2, PTGER3 | ALDH1A1 608/4885KDM4E 2597/4885HPGD 517/4885 |
| US-20100004240-A1 | Indole Compounds | IDO1, TPH1, IDO2 | ALDH1A1 515/4885KDM4E 1622/4885HPGD 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.